{"id":16432,"date":"2026-05-19T09:08:52","date_gmt":"2026-05-19T07:08:52","guid":{"rendered":"https:\/\/www.interpharma.ch\/?p=16432"},"modified":"2026-05-19T09:16:22","modified_gmt":"2026-05-19T07:16:22","slug":"acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/","title":{"rendered":"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne"},"content":{"rendered":"\n

Au cours des dix derni\u00e8res ann\u00e9es, l’acc\u00e8s aux m\u00e9dicaments innovants s’est d\u00e9t\u00e9rior\u00e9 en Suisse. Depuis 2018, l’acc\u00e8s int\u00e9gral via la liste des sp\u00e9cialit\u00e9s a ainsi recul\u00e9 de 64 \u00e0 50 points de pourcentage. En 2025, les patientes et patients en Suisse continuent de n\u2019avoir acc\u00e8s qu\u2019\u00e0 environ moiti\u00e9 moins de nouveaux m\u00e9dicaments innovants qu\u2019en Allemagne. En revanche, l’acc\u00e8s in\u00e9gal par le biais des remboursements au cas par cas a presque doubl\u00e9 au cours de la m\u00eame p\u00e9riode, passant de 15 % \u00e0 27 %. C\u2019est ce que montrent les r\u00e9sultats de la nouvelle \u00e9tude de l\u2019EFPIA Patient W.A.I.T. Indicator publi\u00e9e le 19\u202fmai 2026.<\/strong><\/p>\n\n\n\n

Le Patients W.A.I.T. Indicator est une analyse annuelle, r\u00e9alis\u00e9e par IQVIA sur mandat de l\u2019EFPIA, qui compare l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments innovants en Europe. Il montre combien de m\u00e9dicaments autoris\u00e9s par l\u2019EMA au cours des quatre derni\u00e8res ann\u00e9es sont effectivement disponibles dans les diff\u00e9rents pays europ\u00e9ens. Pour le W.A.I.T. Indicator 2025, l\u2019acc\u00e8s \u00e0 168 m\u00e9dicaments innovants autoris\u00e9s par l\u2019EMA entre 2021 et 2024 a \u00e9t\u00e9 examin\u00e9.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Pour la Suisse, le r\u00e9sultat du W.A.I.T. Indicator est qu\u2019environ 50% des m\u00e9dicaments innovants autoris\u00e9s par l\u2019EMA entre 2021 et 2024 \u00e9taient enti\u00e8rement disponibles en 2025 par le biais de la liste des sp\u00e9cialit\u00e9s. 27% suppl\u00e9mentaires \u00e9taient disponibles de mani\u00e8re limit\u00e9e par le biais de la prise en charge dans des cas particuliers en vertu des art.\u202f71a \u00e0\u202fd de l\u2019OAMal, tandis que pr\u00e8s d\u2019un quart des m\u00e9dicaments innovants n\u2019arrivent pas du tout en Suisse. \u00c0 noter que la prise en charge dans des cas particuliers en vertu des art.\u202f71a \u00e0\u202fd est con\u00e7ue pour des cas exceptionnels et ne saurait donc remplacer l\u2019acc\u00e8s \u00e0 \u00e9galit\u00e9 via la liste des sp\u00e9cialit\u00e9s.<\/p>\n\n\n\n

L\u2019acc\u00e8s complet \u00e0 environ la moiti\u00e9 des m\u00e9dicaments examin\u00e9s signifie que la Suisse s\u2019est am\u00e9lior\u00e9e de trois points par rapport \u00e0 l\u2019ann\u00e9e pr\u00e9c\u00e9dente, mais la situation reste insatisfaisante: aujourd\u2019hui encore, les patientes et patients ont acc\u00e8s \u00e0 pr\u00e8s de deux fois plus de m\u00e9dicaments innovants en Allemagne qu\u2019en Suisse.<\/p>\n\n\n\n

En remontant un peu plus loin en arri\u00e8re, on constate que l\u2019acc\u00e8s aux m\u00e9dicaments innovants s\u2019est globalement d\u00e9grad\u00e9 en Suisse au cours des 10 derni\u00e8res ann\u00e9es. C\u2019est ainsi que l\u2019acc\u00e8s complet via la liste des sp\u00e9cialit\u00e9s est pass\u00e9 de 64 \u00e0 50% depuis 2018 tandis que dans le m\u00eame temps, l\u2019acc\u00e8s via la prise en charge dans des cas particuliers en vertu des art.\u202f71a \u00e0\u202fd s\u2019est presque multipli\u00e9 par deux, passant de 15% \u00e0 27%.<\/p>\n\n\n\n

\"\"
Sources: graphique d\u2019Interpharma sur la base des donn\u00e9es de l\u2019\u00e9tude de l\u2019EFPIA Patients W.A.I.T. Indicator 2018-2025.<\/figcaption><\/figure>\n\n\n\n

L\u2019am\u00e9lioration minime de l\u2019acc\u00e8s complet via la liste des sp\u00e9cialit\u00e9s observ\u00e9e cette ann\u00e9e ne va probablement pas se poursuivre dans les prochaines ann\u00e9es. En effet, les conditions cadres mondiales se sont profond\u00e9ment transform\u00e9es depuis la p\u00e9riode 2021-2024 examin\u00e9e. La clause de la nation la plus favoris\u00e9e introduite par l\u2019administration am\u00e9ricaine modifie durablement les conditions de lancement de m\u00e9dicaments innovants et donc l\u2019acc\u00e8s \u00e0 ceux-ci. Les effets concrets se manifesteront probablement pour la premi\u00e8re fois dans le W.A.I.T. Indicator 2026 (p\u00e9riode \u00e9tudi\u00e9e 2022-2025).<\/p>\n\n\n\n

Dans ce contexte, il est actuellement d\u2019autant plus important de renoncer \u00e0 toute mesure politique de nature \u00e0 limiter encore plus l\u2019acc\u00e8s aux m\u00e9dicaments innovants. Il faut au contraire moderniser le syst\u00e8me de formation des prix et mettre en \u0153uvre avec d\u00e9termination l\u2019acc\u00e8s d\u00e8s le jour\u202f0.<\/p>\n\n\n\n

EFPIA Patients W.A.I.T. Indicator 2025 Survey<\/a><\/p>\n\n\n\n

Le W.A.I.T. Indicator de l\u2019EFPIA se limite aux nouvelles substances actives et ne tient pas compte des nouvelles indications. Sa pertinence r\u00e9elle est donc limit\u00e9e.<\/strong><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Au cours des dix derni\u00e8res ann\u00e9es, l’acc\u00e8s aux m\u00e9dicaments innovants s’est d\u00e9t\u00e9rior\u00e9 en Suisse. Depuis 2018, l’acc\u00e8s int\u00e9gral via la liste des sp\u00e9cialit\u00e9s a ainsi recul\u00e9 de 64 \u00e0 50 points de pourcentage. En 2025, les patientes et patients en Suisse continuent de n\u2019avoir acc\u00e8s qu\u2019\u00e0 environ moiti\u00e9 moins de nouveaux m\u00e9dicaments innovants qu\u2019en Allemagne. […]<\/p>\n","protected":false},"author":7,"featured_media":16430,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[120,127],"class_list":["post-16432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-innovation-fr","tag-acces-des-patients"],"acf":[],"yoast_head":"\nAcc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne\" \/>\n<meta property=\"og:description\" content=\"Au cours des dix derni\u00e8res ann\u00e9es, l’acc\u00e8s aux m\u00e9dicaments innovants s’est d\u00e9t\u00e9rior\u00e9 en Suisse. Depuis 2018, l’acc\u00e8s int\u00e9gral via la liste des sp\u00e9cialit\u00e9s a ainsi recul\u00e9 de 64 \u00e0 50 points de pourcentage. En 2025, les patientes et patients en Suisse continuent de n\u2019avoir acc\u00e8s qu\u2019\u00e0 environ moiti\u00e9 moins de nouveaux m\u00e9dicaments innovants qu\u2019en Allemagne. […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T07:08:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T07:16:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"659\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"lukaskuemmerli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"lukaskuemmerli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\"},\"author\":{\"name\":\"lukaskuemmerli\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf\"},\"headline\":\"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne\",\"datePublished\":\"2026-05-19T07:08:52+00:00\",\"dateModified\":\"2026-05-19T07:16:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\"},\"wordCount\":716,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png\",\"keywords\":[\"Innovation\",\"Acc\u00e8s des patients\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\",\"name\":\"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png\",\"datePublished\":\"2026-05-19T07:08:52+00:00\",\"dateModified\":\"2026-05-19T07:16:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png\",\"width\":1199,\"height\":659},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf\",\"name\":\"lukaskuemmerli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g\",\"caption\":\"lukaskuemmerli\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/","og_locale":"fr_FR","og_type":"article","og_title":"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne","og_description":"Au cours des dix derni\u00e8res ann\u00e9es, l’acc\u00e8s aux m\u00e9dicaments innovants s’est d\u00e9t\u00e9rior\u00e9 en Suisse. Depuis 2018, l’acc\u00e8s int\u00e9gral via la liste des sp\u00e9cialit\u00e9s a ainsi recul\u00e9 de 64 \u00e0 50 points de pourcentage. En 2025, les patientes et patients en Suisse continuent de n\u2019avoir acc\u00e8s qu\u2019\u00e0 environ moiti\u00e9 moins de nouveaux m\u00e9dicaments innovants qu\u2019en Allemagne. […]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/","og_site_name":"Interpharma","article_published_time":"2026-05-19T07:08:52+00:00","article_modified_time":"2026-05-19T07:16:22+00:00","og_image":[{"width":1199,"height":659,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png","type":"image\/png"}],"author":"lukaskuemmerli","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"lukaskuemmerli","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/"},"author":{"name":"lukaskuemmerli","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf"},"headline":"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne","datePublished":"2026-05-19T07:08:52+00:00","dateModified":"2026-05-19T07:16:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/"},"wordCount":716,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png","keywords":["Innovation","Acc\u00e8s des patients"],"inLanguage":"fr-FR","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/","name":"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png","datePublished":"2026-05-19T07:08:52+00:00","dateModified":"2026-05-19T07:16:22+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Screenshot-2026-05-18-122934.png","width":1199,"height":659},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/acces-aux-medicaments-innovants-la-suisse-continue-de-stagner-derriere-lallemagne\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Acc\u00e8s aux m\u00e9dicaments innovants: la Suisse continue de stagner derri\u00e8re l\u2019Allemagne"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf","name":"lukaskuemmerli","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g","caption":"lukaskuemmerli"}}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=16432"}],"version-history":[{"count":3,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16432\/revisions"}],"predecessor-version":[{"id":16450,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16432\/revisions\/16450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/16430"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=16432"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=16432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}